Dr. Hong Xin graduated from Dalian Medical University major in clinical medicine in 1994 and got her master degree major in pharmacology in 1997. She went to Japan sponsored by Japanese Ministry of Education Scholarship in 2000 and obtained her Ph.D degree from Gunma University, Graduate School of Medicine in 2005. After worked in Jikei medical University in Tokyo, Dr. Xin joined Fudan University, School of pharmacy in 2008, carrying teaching and research work in Department of pharmacology. Her research work focused on mechanism of anti-inflammatory and immune, cancer multidrug resistance. Her research work was supported by 4 grants such as The National Natural Science Fund, and published 24 papers with the highest inpact factor were 7.4. She also worked in National Health and Family Planning Commission of the People’s Republic of China for half and two years managing National Science and Technology Major Project.
Oncological pharmacology; Anti-inflammatory; Immunological pharmacology
Education
2000.1 ~ 2005.3 Gunma University, Graduate School of Medicine, Japan, Doctor Degree, Major in Pharmacology
1994.9 ~ 1997.7 Dalian Medical University, China, Master Degree, Major in Pharmacology
1989.9 ~ 1994.7 Dalian Medical University, China, Bachelor Degree, Major in Clinical medicine
Professional Experiences
2008.9 ~ Present Lecture and associate professor, Department of pharmacology, School of Pharmacy, Fudan University, China.
2006.5 ~ 2008.9 Postdoctoral fellow, Department of pharmacology, School of Pharmacy, Fudan University, China.
2005.4 ~ 2006.3 Researcher, DDS (Drug Delivery System) Institute, Jikei University, School of Medicine, Japan
1997.7 ~ 2000.1 Lecturer, Department of Pharmacology, Dalian Medical University, China
Grants & Projects
National Natural Science Foundation of China (Grant No. 81573655)
Ph.D. Programs Foundation of Ministry of Education of China (Grant No. 20090071120065)
Shanghai Pujiang talent program (Grant No. 06PJ14018)
China Postdoctoral Science Foundation (Grant No. 20060400581）
Memberships
Society for Chinese Pharmacology
Selected Publications（latest 5 yrs，<20 papers）
1. Wang M#, Xin H#, Tang W, Li Y, Zhang Z, Fan L, Miao L, Tan B, Wang X, Zhu YZ. AMPK Serves as a Therapeutic Target Against Anemia of Inflammation. Antioxid Redox Signal. 2017 Aug 10;27(5):251-268.
2. Xin H, Wang M, Tang W, Shen Z, Miao L, Wu W, Li C, Wang X, Xin X, Zhu Y. Hydrogen sulfide attenuates inflammatory hepcidin by reducing IL-6 secretion and promoting SIRT1-mediated STAT3 deacetylation. Antioxid Redox Signal. 2016 Jan 10;24(2):70-83.
3. Wu T, Zhong L, Hong Z, Li Y, Liu X, Pan L, Xin H*, Zhu Y*. The effects of Zanthoxylum bungeanum extract on lipid metabolism induced by sterols. J Pharmacol Sci. 2015;127(3):251-9. (co-corresponding author)
4. Xin H, Wang K, Hu G, Xie F, Ouyang K, Tang X, Wang M, Wen D, Zhu Y, Qin X .Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts. PLoS One. 2014 , 9;9(1)
5. Xin H, Kong Y, Zhou YJ, Li DP, Tan WF*. Lignans extracted from Vitex negundo possess cytotoxic activity by G2/M phase cell cycle arrest and apoptosis induction. Phytomedicine，2013, 15; 20(7):640-7.
6. Huang S#, Xin H#, Sun J, Li R, Zhang XM, Zhao D*. The ERβ agonist diarylpropionitrile inhibits LPS-induced RANTES production in macrophages by repressing the NF-κB activation. Fertil Steril. 2013, 100(1):234-40.
7. Xin H, Kong Y, Jiang X, Wang K, Qin X, Miao ZH, Zhu Y, Tan W. Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell propertie. J Pharmacol Sci. 2013;122(4):299-304
